Last Updated : January 24, 2018
Details
FilesGeneric Name:
insulin degludec
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus, Type 1 & 2
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Tresiba
Project Line:
Reimbursement Review
Project Number:
SR0521-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Diabetes mellitus, Type 1 & 2
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2 |
|
---|---|
Call for patient input posted3 | May 02, 2017 |
Patient group input closed3 | June 21, 2017 |
Clarification:
- Patient input submission received |
|
Patient input summary sent for review to patient input groups | July 25, 2017 |
Patient group comments on input summary closed | August 01, 2017 |
Clarification:
- Patient input summary feedback received |
|
Submission received | May 31, 2017 |
Submission accepted for review | June 14, 2017 |
Review initiated | June 15, 2017 |
Draft CDR review report(s) sent to applicant | September 01, 2017 |
Comments from applicant on draft CDR review report(s) received | September 13, 2017 |
Redaction requests from applicant on draft CDR review report(s) received | September 20, 2017 |
Clarification:
- No redaction requests from applicant received |
|
CDR review team's comments on draft CDR review report(s) sent to applicant | October 05, 2017 |
Canadian Drug Expert Committee (CDEC) meeting | October 18, 2017 |
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | October 30, 2017 |
Embargo4 period ended and validation of redacted CDR review report(s) received | November 13, 2017 |
CDEC Final Recommendation issued to applicant and drug plans | November 20, 2017 |
CDEC Final Recommendation posted5 | November 22, 2017 |
Final CDR review report(s) and patient input posted5 | December 15, 2017 |
Files
Last Updated : January 24, 2018